Science & Enterprise subscription

Follow us on Twitter

  • A research institute is developing sensors made with graphene, worn like a patch on the skin, and connect to a mob… https://t.co/UcadIhMQUm
    about 12 hours ago
  • New post on Science and Enterprise: Institute Developing Phone-Linked Graphene Sensors https://t.co/EsUFwv30JF #Science #Business
    about 13 hours ago
  • An agricultural research lab uses genetic engineering and gene silencing to produce crop plants that increase thei… https://t.co/Mp1I9MmmxA
    about 17 hours ago
  • New post on Science and Enterprise: Genetic Engineering, Silencing Boosts Plant Output https://t.co/xNJlN5xbFp… https://t.co/Rg4cRQPiAd
    about 17 hours ago
  • New post on Science and Enterprise: Scenes From the AAAS Meeting, Fun With Science https://t.co/uOsGny4jma #Science #AAASmtg
    about 1 day ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Trial Results Show Gene Transfers Reverse Sickle Cell Disease

Gene therapy lab

Results from the first 2 participants in a clinical trial show transferring healthy genes to patients with sickle cell disease reverses symptoms of the disease that continues for up to 1 year. . . . → Read More: Trial Results Show Gene Transfers Reverse Sickle Cell Disease

Janssen Licensing Cancer Antibodies in $1.8B Deal

Llama

An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal

Trials OK’d for Inherited Eye Disease Therapy with Crispr

Crispr-Cas9 illustration

The company developing a treatment for a rare inherited eye disease using the genome editing technique Crispr received authorization from the Food and Drug Administration to begin clinical trials. . . . → Read More: Trials OK’d for Inherited Eye Disease Therapy with Crispr

Update – Verily Suspends Glucose-Sensing Contact Lens Project

Smart contact lenses

An initiative developing a contact lens that measures blood glucose levels in tear fluid is now on hold, according to Verily Life Sciences, a division of Alphabet, the parent company of Google. . . . → Read More: Update – Verily Suspends Glucose-Sensing Contact Lens Project

Gene Silencing Technology Licensed in $3.7B Deal

RNA strand illustration

Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal

BASF Licensing Precise Crispr Editing from Broad Institute

Crispr-Cas9 illustration

The global chemical company BASF is licensing a more precise form of genome editing from the Broad Institute, a genetics research center affiliated with Harvard University and MIT. . . . → Read More: BASF Licensing Precise Crispr Editing from Broad Institute

Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Human lungs illustration

A company in Maryland developing alternatives to human organ transplants is licensing a technology to help create 3-D printed lungs for transplantation with bioinks derived from tobacco plants. . . . → Read More: Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Handshake

Drug maker AbbVie and biotechnology company Morphic Therapeutic are collaborating on new treatments for fibrosis based on Morphic’s technology blocking proteins that promote fibrosis. . . . → Read More: Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

T-cells illustration

A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

Biotech in $3.7B Licensing Deal for Hepatitis-B

Hepatitis-B virus

A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B